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Fibrosis is a general complication inmany diseases. It is the main complication during peritoneal dialysis (PD) treatment, a therapy
for renal failure disease. Local inflammation and mesothelial to mesenchymal transition (MMT) are well known key phenomena
in peritoneal damage during PD. New data suggest that, in the peritoneal cavity, inflammatory changes may be regulated at least in
part by a delicate balance between T helper 17 and regulatory T cells. This paper briefly reviews the implication of the Th17/Treg-
axis in fibrotic diseases. Moreover, it compares current evidences described in PD animal experimental models, indicating a loss
of Th17/Treg balance (Th17 predominance) leading to peritoneal damage during PD. In addition, considering the new clinical
and animal experimental data, new therapeutic strategies to reduce the Th17 response and increase the regulatory T response are
proposed.Thus, future goals should be to develop new clinical biomarkers to reverse this immunemisbalance and reduce peritoneal
fibrosis in PD.
1. Introduction
An effective inflammatory response is essential not only
for the resolution of infections but also for wound healing
after injury. The repair is mediated by the collaboration
of various mechanisms launched by an acute inflammatory
reaction. This process implicates the release of chemokines
and cytokines and the migration of various cells of the
immune system. If a sustained inflammatory reaction that
is not resolved properly becomes chronic, it could lead
to fibrosis due to the accumulation of extracellular matrix
(ECM) components [1].
Peritoneal dialysis (PD) is a form of renal replacement
therapy alternative to haemodialysis that is widely used
around the world for patients suffering from renal failure
disease [2, 3]. The process uses the peritoneum as a semiper-
meable membrane across which PD fluids (PDFs) and dis-
solved substances (electrolytes, urea, glucose, and other small
molecules) are exchanged from the blood [4]. The peritoneal
membrane (PM) acts as a protective barrier against injury
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and pathogens, where humoural and cellular responses are
generated.The treatment consists of the instillation and peri-
odical renovation of a hyperosmotic PDF in the peritoneal
cavity through a permanent installed catheter. However, the
mechanical damage due to PDF instillation and the exposure
of peritoneal cells to glucose degradation products (GDPs)
and advanced glycation end products (AGEs) (due to the
nonphysiological nature of this PDF) generates inflamma-
tion. Along these lines, it has been demonstrated in vitro
that GDPs andAGEs stimulate NF𝜅B-mediated transcription
and the secretion of cytokines and chemokines by human
peritoneal mesothelial cells [5]. In addition, the presence of
the catheter [6] and peritonitis episodes during treatment
[7] appears to be responsible for various alterations of the
PM structure and functionality. The final consequence is the
generation of vascular alterations [8] and peritoneal fibrosis
[3, 9], leading to an ultrafiltration failure [10, 11] that impedes
the dialysis process (Figure 1). Although in recent decades
great effort has been made to improve catheter design [6]
and the biocompatible solutions used [12–14], complications
are still common [15, 16]. It has also been demonstrated that
inflammation is present in PD patients. Increased serum con-
centrations of IL-6, TNF-𝛼, VEGF, and C-reactive proteins
have been reported in patients, suggesting that PD leads
to increased systemic inflammation [17]. Moreover, there is
evidence in animal models of chronic peritoneal exposure to
PDF showing that this procedure induces PM inflammation
and fibrosis [18]. The use of an anti-inflammatory drug
(a Cox-2 inhibitor) reduced this peritoneal inflammatory
response and consequently the fibrosis. This result confirms
the role of inflammation in peritoneal fibrosis [19].
Inflammation is driven by various cell populations
including macrophages, neutrophils, and lymphocyte sub-
sets. The differentiation of T cells is crucial for immune
and inflammatory responses and its regulation may be a
therapeutic target to control peritoneal damage. It has been
found that there are different rates between CD4+ and CD8+
cells in the peritoneum during PD with respect to healthy
individuals [20]. It has been postulated that the presence
of AGEs is responsible for an increase in the population of
CD8+ (T cytotoxic) lymphocytes [21]. Regarding CD4+ (T
helper) subsets, in general termsTh1 cells produce high levels
of IFN-𝛾, while Th2 cells secrete predominantly IL-4 [22].
There is some controversy about the pattern of response that
is generated in patients undergoing treatment with PDF. It
is described that there is a deviation toward Th2 pattern
of PD in stable patients [23]. However, during episodes of
acute peritonitis, a Th1 immune response is developed [24,
25]. In addition to these two classical T helper cell subsets
(Th1 and Th2), a third and fourth subpopulation, designated
regulatory T (Treg) andT helper 17 (Th17) cells, have emerged
as independent differentiation pathways [26, 27]. While the
predominance of Th17 cells induces the secretion of a large
number of proinflammatory cytokines, Treg cells restrict
inflammatory responses and are associated with immune-
tolerance [28]. Very little is known about the involvement of
these subpopulations in the deterioration of the peritoneum
during dialysis. The imbalance between these situations may
cause fibroproliferative diseases and could be an important
cause of morbidity and mortality.
In this review we discuss the implication of Th17 and
Treg cells in kidney function and fibrotic diseases in different
animal experimentation models. More specifically we will
focus on the origin of peritoneal damage and its relationship
with the intraperitoneal presence of these particular subsets
of T lymphocytes, as well as on its clinical implication in
peritoneal damage in PD patients, which frequently results
in an inability to continue with the treatment.
2. T Helper 17 and Regulatory T Cell
Differentiation and Their Plasticity
Th17 cells represent a subset of T helper cells that secrete
mainly interleukin- (IL-) 17 as well as other proinflam-
matory cytokines, and they have been related to many
autoimmune and chronic inflammatory diseases [29]. There
is a balance between Th17 and Treg cells that depends on
the activation of the transcription factor ROR𝛾t (factors
retinoic acid receptor-related orphan receptor 𝛾t) and Stat3
(signal transducer and activator of transcription 3), or FoxP3
(forkhead box P3) and Stat5, respectively, which regulate the
immune response through the secretion of pro- and anti-
inflammatory cytokines [30–33]. On the other hand, the
importance of Treg cells to the maintenance of peripheral
tolerance under noninflammatory conditions throughout life
has also been confirmed. In fact, mice lacking Treg cells
presented a fatal inflammatory response [34, 35].
The main cytokines involved in Th17/Treg balance are
the TGF-𝛽 (transforming growth factor beta) and IL-6
(interleukin-6) [27, 36, 37]. IL-6 is strongly induced in
cells of the innate immune system upon stimulation of
pattern recognition receptors such as toll like receptors (TLR)
or C-type receptors. It has been shown that mice lacking
IL-6 present a deficiency in the differentiation of effector
T cells [38, 39]. TGF-𝛽 in the absence of IL-6 induces
Foxp3, thus pushing T-cell differentiation away from the
Th17 transcriptional program and decidedly toward the Treg
lineage [33]. Moreover, in the central nervous system, TGF-𝛽
without the synergy of IL-6 will force T cells to differentiate
through the T regulatory cell lineage [40]. In contrast, the
proinflammatory cytokine IL-6 in the absence of TGF-𝛽
activates Stat3 by phosphorylating it, which overcomes Foxp3
inhibition of ROR𝛾t transcriptional activity. This process
leads to the upregulation of the IL-23R, thus pushing T-
cell differentiation toward a Th17 fate [33]. Therefore the
cytokine environment is essential for the predominance of an
inflammatory or an anti-inflammatory response (Figure 2).
3. Th17 and Tissue Fibrosis
Fibroproliferative diseases such as idiopathic pulmonary,
liver, cardiovascular, and renal fibrosis are usually associated
with chronic inflammation, as has been described previously
[41–45]. When an inflammatory response becomes chronic,
the accumulation of ECM is more extensive and the function
of the organ is compromised. A number of studies have
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Figure 1: PM schemas and biopsies representing the normal peritoneal structure and its changes during PD. Possible therapeutic
approaches. (a) and (b) are adapted with permission fromAguilera et al. (2013).Available from http://www.intechopen.com/books/the-latest-
in-peritoneal-dialysis/the-mesothelial-to-mesenchymal-transition-a-pathogenic-and-therapeutic-key-for-peritoneal-membrane-f [80]. (a)
Realistic representation of a healthy peritoneal cavity. A preservation of the mesothelial layer is clearly seen, only a few fibroblasts and
vessels are visible, and only a small layer of extracellular matrix lies in the compact zone of the muscle layer. (b) After exposure to PD
liquids, the structure of the PM starts to change dramatically with the appearance of more fibroblasts, macrophages, and inflammatory
cytokines and finally with deposition of more extracellular matrix (ECM) cells. Inflammation and fibrosis will be the result of these changes.
Some drugs like COX-2 inhibitors, PPRA𝛾 agonists, or RAS targeting are possible therapeutic strategies to protect from PD complications
such as inflammation, angiogenesis, fibrosis, and/or MMT. (c) A peritoneal biopsy of a mouse peritoneal membrane that was treated with
physiological saline is shown as control. The PM is well preserved and fibrotic response is absent. (d) Peritoneal biopsy of a mouse PM that
was exposed to PDF for 40 days. A significant fibrotic response can be observed with a larger ECM and many inflammatory cells.
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Figure 2: Mechanisms of Th17/Treg-balance in the peritoneal cavity in PD. Th17 predominance. In the peritoneal cavity local factors
activate dendritic cells, macrophages, and neutrophils to produce proinflammatory molecules (IL-6, TNF𝛼, TGF-𝛽, VEGF, chemokines,
and prostaglandins). Immune cells and proinflammatory molecules are reciprocally activated; thus cells induce proinflammatory molecule
release and vice versa. These molecules activate Th17 cells and IL-17 production, which may result in fibrosis and MMT. This occurs in the
presence of continuously high TGF-𝛽 levels. In contrast, in the presence of inactive immune cells together with low IL-6 levels, Treg cells
are activated, releasing IL-10 and TGF-𝛽 that may block MMT. Abbreviations: GDPs: glucose-derived products. IP: intraperitoneal. AGEs:
advanced glycation end products.
highlighted the roles of Th17/Treg/Th1/Th2 responses in
the pathogenesis of tissue fibrosis [46, 47]. Among these
responses, Th17 cells may mediate strong inflammation by
producing a cocktail of cytokines such as IL-6, IL-17A, IL-17F,
and IL-22, amongwhich IL-17A has been characterized as the
major effector cytokine in causing a sustained inflammatory
response.
Recent studies have investigated the role ofTh17 response
in fibrosis. It has been reported that administration of IL-17A
in vitro increased the synthesis and secretion of collagen in
alveolar epithelial cells in a pulmonary fibrosis model. More-
over, all IL-17-associated signaling pathways were mainly
activated in fibrotic lung biopsies, and a blockade of IL-17A
attenuated tissue injury, inflammation, and fibrosis in acute
and chronic injuries [48].
Furthermore, IL-17 has also been reported to be involved
in the pathogenesis of chronic liver fibrosis [44, 49–51]. The
same mechanism was proposed in another study on liver
damage in chronic hepatitis B patients who presented an
elevatedTh17 cells population [52].
Th17 cells also play a crucial role in autoimmune
myocarditis, as based on in vitro and in vivo experiments
which confirm that IL-17 induced cardiac fibrosis by acti-
vating the protein kinase C-𝛽/Erk1/2/NF-𝜅B pathway [53].
Moreover, the regulatory molecule CD69, through the reg-
ulation of Th17 effector responses, limits myocardial inflam-
mation, fibrosis, and subsequent heart failure [54].
Recent studies have shown the importance of Th17 cells,
and the hallmark cytokine IL-17A, in immune-mediated
glomerulonephritis, including experimental antimyeloper-
oxidase glomerulonephritis, crescentic glomerulonephritis,
and lupus nephritis [55, 56]. Th17 cells participate in renal
damage, as demonstrated by an experimental study in mice
showing that Th17 cell injection caused albuminuria and
neutrophils infiltration in the kidney [57]. Recent studies
also show the presence of Th17 cells and elevated renal
production of IL-17A in nonimmune experimental renal
diseases, including a model of unilateral ureteral obstruction
[58]. In experimental ischaemia reperfusion, neutrophils, but
notTh17 cells, were themain sources of IL-17A and contribute
to renal injury by natural killer T activation and IL-12/IFN-𝛾
production [59]. In renal allograft rejection, positive staining
for IL-17A has been detected in tubular cells [60], as we
have observed in an experimental model of CCN2-mediated
renal damage, suggesting that renal cells could produce this
cytokine and contribute to extending the damage. With this
model we recently demonstrated that a blockade of IL-17A
diminished renal inflammation [58].
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Based on all the above studies, IL-17 has been proposed
as a drug target in many fibrotic diseases [61].
4. Regulatory T Cells and Tissue Fibrosis
Although an induced Th17 response is connected to fibro-
genesis, a relative decrease in the number of Treg cells may
also be involved in the pathogenesis of inflammatory and
fibrotic diseases. The evaluation of these cells in the context
of experimentally induced fibrosis has been challenging, and
Treg depletion in mice has been demonstrated to attenuate
the development of lung fibrosis [62].Moreover, in an experi-
mental animalmodel of cardiac fibrosis, the depletion of Treg
cells and/or adoptive transfer of isolated Tregs ameliorated
cardiac fibrosis, indicating a protective role of regulatory T
cell in tissue fibrosis [63]. Recently, it has been reported that
Treg cells are essential for preventing from accumulation of
fibrocytes and collagen deposition in a pulmonary disease
animal model. In this study, it was shown that a blockade
of Treg cells increased the accumulation of solid collagen
and progression of the disease [64]. Finally, in another study
(Keloid fibrotic disease) the potential role of Treg cells in
attenuating collagen synthesis was investigated. This group
found that the imbalance of Tregs may contribute to the
development of this fibrotic disease and that the correction
of this imbalance may be of therapeutic value [65].
5. Th17 and Treg Lymphocyte Subsets in
the Peritoneal Cavity on PD
PD-related factors locally stimulate Th17 cells and can be
subdivided into two groups: exogenous and endogenous.
The exogenous factors include bacteria and their derivatives,
which enter into the peritoneal cavity through PD-catheter
or via intestinal translocation and can provoke peritonitis
episodes [66]. Peritoneal endogenous factors such as AGEs
[67] could be involved in the induction of IL-17 levels
by activating IL-6 and TGF-𝛽 proinflammatory cytokines,
respectively. Although there is little data regarding how
advanced glycation end products (AGEs) are implicated in
peritoneal dialysis damage, their implication in posttrans-
plantation and diabetic kidneys showed an induction of IL-
6 and TGF-𝛽, which are promoters of Th17 differentiation
(Figure 2). Thus, it is plausible that the induced Th17 activity
may have a poor fate in peritoneal damage during peritoneal
dialysis. In nondiabetic PD patients, an elevation of IL-
17 in peritoneal cavity effluents followed by a peritonitis
episode was demonstrated [66], which is one of the main
complications that lead to peritoneal fibrosis in PD patients
[3].
Currently, it is accepted that mesothelial to mesenchy-
mal transition (MMT) is a key process in PM survival in
PD. Mesothelial cells lose their basolateral and basoapical
polarity, acquiring a fibroblastoid phenotype with migration
capacity. The cells invade the submesothelial compact zone
where they synthesize ECMandVEGF, which are responsible
for fibrosis and angiogenesis, respectively [68, 69]. IL-17 itself
is capable of inducing epithelial to mesenchymal transition
in bronchial cells [70]. Although this effect has not been
demonstrated in the peritoneum, it is very likely that IL-17
also contributes to PM deterioration via MMT induction.
The definitive evidence on IL-17 involvement in PM
damage on PDwas recently provided by Rodrigues-Dı´ez et al.
(2014). This study demonstrated in both mice and human
samples that IL-17 is overexpressed in peritoneal biopsies.
This was the first report to demonstrate that IL-17 participates
in the typical fibrotic changes suffered in PM during long-
term PD (induced fibronectin, 𝛼-smooth muscle actin, and
fibroblast specific protein-1 expression). Moreover, to better
elucidate the effects of IL-17 on PM, intraperitoneal IL-17
was injected in mice, reproducing the changes that normally
take place in PD patients. On the other hand, the use of
a neutralizing IL-17A antibody injected intraperitoneally in
mice exposed to PDF for 35 days blockaded the anatomical
changes in the PM and reduced peritoneal fibrosis [71].
On the other hand, Treg cells are strongly connected
with immune tolerance. Patients in end-stage renal disease
with their suppressed immune response suffer impaired Treg
cell responses [72]. Currently, there is not much evidence
regarding the role of Treg cells in the peritoneal cavity during
PD. To our knowledge, there is one study focusing on the
function of Treg cells on peritoneal damage. This study
concluded that rosiglitazone, a PPAR𝛾 agonist, augments
the intraperitoneal IL-10 levels (Treg-associated cytokine),
increases the recruitment of CD4+ CD25+ FoxP3+ (regula-
tory T cells), and finally attenuates peritoneal fibrosis in an
experimental mouse PD model [73].
Evidence suggests that Th17 cells share common progen-
itors with Treg cells and that the developmental pathways
of these two subsets are reciprocally regulated [74]. In fact,
it has been recently demonstrated that a reduction in IL-
17 secretion due to Treg cell activation is associated with
a diminished fibrotic response specifically in PD. The vita-
min D pathway has been shown to regulate inflammatory
responses. In regard to this, the effect of paricalcitol, a
vitamin D receptor activator, was tested in a mouse model
of PD to evaluate its effect on inflammatory cells and on the
outcome of peritoneal fibrosis. It was found that the group
that was treated with PDF presented increased levels of IL-
17 cytokine in the peritoneal effluents compared with the
group that was treated with paricalcitol diluted in the PDF.
Moreover, the increased IL-17 concentration was perfectly
correlated with the thickness of the peritoneum, meaning
IL-17 is a profibrotic cytokine. This effect was related to an
increased number of Tregs in the group that was treated with
paricalcitol [75].
6. Therapeutic Approaches to
Prevent Peritoneal Damage Using
the Th17/Treg-Axis: From Animal
Models to PD Patients
Accepting the evidence above that Th17 and Treg subsets
are involved in peritoneal damage in PD, we propose the
following therapeutic strategies.
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Figure 3: Therapeutic approaches to prevent peritoneal damage
using the Th17/Treg-axis as a target. One of the most important
modulators of Th17/Treg activity is the concentration of branch
chain amino acids (BCAA). Although the data in relation to BCAA
plasma levels in a uraemic state are contradictory, many articles
indicate that these amino acids are decreased in uraemia due to
systemic acidosis, inflammation, amino acidmisbalances, and liquid
overload. Normal or relative normal BCAA levels activate anmTOR
(mammalian Target of Rapamycin) cascade including HIF1 and
ROR𝛾t and subsequently IL-17 and IL-23 production. Rapamycin,
an mTOR inhibitor, would block this cascade, thus providing
an anti-inflammatory/antifibrotic and possibly anti-MMT effect.
Moreover, PPAR𝛾 agonists can also inhibit Th17 differentiation
through a direct blockade of Stat3 transcription factor and HIF-1.
Ultimately ROR𝛾t is downregulated, and IL-17 and IL-23 production
is decreased. However the PPRA𝛾 agonists are also able to act
on the anti-inflammatory cascade. In the peritoneal cavity in PD,
rosiglitazone augments IL-10 levels and Treg activity (upregulation
of FoxP3+). This process could be one of the most important
mechanisms by which PPRA𝛾 agonists protect the PM. In addition,
paricalcitol, a specific vitamin D activator, has been recently shown
to inhibit IL-17 production and PM fibrosis and possibly decrease
MMT. Finally, celecoxib, a Cox2 inhibitor, decreases IL-17 produc-
tion by blocking the E2 prostaglandin levels and thus attenuates the
PM damage induced by PDF.
6.1. Use Drugs and Molecular Strategies
6.1.1. mTOR Inhibitors. The mTOR inhibition by Rapamycin
may diminish IL-17 production. The mTOR activation
induces hypoxia induced factor-1 (HIF-1) and ROR𝛾t activa-
tion and subsequently IL-17 and IL-23 production [76].Thus,
these drugs may provide an anti-inflammatory/antifibrotic
effect and possibly an anti-MMT action as was demonstrated
by Aguilera et al. [77] (Figure 3).
6.1.2. Peroxisome Proliferator-Activated Receptors- (PPAR-) 𝛾
Agonists. The use of PPAR𝛾 agonists, for example, rosiglita-
zone, may be a therapeutic alternative to prevent peritoneal
damage [78].These receptors show a double protective effect.
First, they inhibit the Th17 differentiation via a Stat3 cascade
blockade, which results in a downregulation of ROR𝛾t and
a decrease in IL-17 production [79]. Moreover, in an animal
model study in which the effect of rosiglitazone in the
preservation of the peritoneal membrane was investigated, it
was found that rosiglitazone augmented the intraperitoneal
IL-10 levels (Treg-associated cytokine) and increased the
recruitment of CD4+ CD25+ FoxP3+ (regulatory T cells) [73]
(Figure 3).
6.1.3. Vitamin D Receptor Activators. Another interesting
drug that could ultimately have a beneficial effect on PM in
PD is paricalcitol. Using a mice PD model, it was demon-
strated that the PM thickening was reduced in mice treated
with paricalcitol in comparison with the nontreated group.
Moreover, in the effluents of mice treated with paricalcitol,
an increased number of Treg cells and lower IL-17 levels were
found in comparison with the nontreated group. In addition,
the IL-17 levels measured in peritoneal effluent showed a
positive linear correlation with the PM thickness [75]. These
data suggest a direct involvement of IL-17 in peritoneal injury
and paricalcitol may act on this target (Figure 3).
6.1.4. COX-2 Inhibitors. Celecoxib, a cyclooxygenase- (Cox-)
2 inhibitor agent, was shown to prevent the PM damage in
PD when administrated orally to a group of mice in PD,
acting directly on the inflammatory cascade in general. After
5 weeks of treatment, the celecoxib group showed a fibrotic
response similar to healthy controls, while the untreated
group exposed to PD only developed considerable fibrosis
[19] (Figure 3).
7. Discussion
One of the most devastating complications of PD treatment
is peritoneal fibrosis. The endogenous and exogenous fac-
tors mentioned above related to PDF generate a chronic
inflammatory response in the peritoneal cavity. The balance
between Th17 and Treg cells is guided by proinflammatory
cytokines secreted from Th17 cells and anti-inflammatory
cytokines produced from regulatory T cells. Any factor that
may alter this balance can lead to peritoneal deterioration
and finally to peritoneal damage. The high levels of var-
ious proinflammatory molecules such as IL-6 and TGF-𝛽
cytokines during PD create an environment that induces a
chronic inflammatory condition in the peritoneal cavity and
generates peritoneal fibrosis. This emergent concept suggests
that the immune imbalance is the fundamental key for PM
deterioration in PD.
Moreover, Th17 signaling with high IL-17 levels has been
implicated in the aetiology of several types of inflammatory
and fibrotic diseases. Therefore, components of the IL-17 and
Treg cells pathway are considered highly “druggable” and are
important targets for the treatment of these inflammatory
and fibrotic diseases. Current evidence indicates that IL-
17 inhibition and Treg activation are logical therapeutic
strategies for the treatment of animal peritoneal fibrosis
[71, 73, 75].
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In conclusion, the importance of developing new thera-
pies to protect the peritoneal membrane blocking the IL-17
secretion or activating the Treg pathway has been demon-
strated. Some novel therapeutic strategies tested in animal
models and in vitro include the administration of m-Tor
inhibitors, PPAR𝛾 agonists, vitamin D receptor activators,
and Cox-2 inhibitors. Lessons learned from regulators of
Th17/Treg-axis may aid in the future clinical implementation
of these agents with the goal of reducing peritoneal fibrosis
and improving patients’ life undergoing PD.
8. Conclusion
PD-related factors are responsible for Th17 activation/Treg
deactivation in the peritoneal cavity during peritoneal dial-
ysis. The Th17/Treg-axis is important for maintaining the
anatomical and functional integrity of the PM.Therefore, the
Th17/Treg-axis may be considered a future therapeutic target.
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